Navigation Links
Indeterminate breast lesions found in high-risk patients should be evaluated aggressively to exclude malignancy
Date:5/3/2010

Short-term follow-up is often used to evaluate indeterminate breast lesions found on breast magnetic resonance imaging (MRI). However, researchers have found that indeterminate lesions (found in women with a high risk of breast cancer) should be evaluated sooner to exclude a possible malignancy, according to a study to be presented at the ARRS 2010 Annual Meeting in San Diego, CA.

Breast lesions that cannot be definitively classified as suspicious for malignancy or benign are considered indeterminate. "A short-term follow-up MRI, ultrasound, and/or mammographic investigation is usually recommended for indeterminate lesions found in high-risk women," said Martin Korzeniowski, MD, lead author of the study. "However, that may not be soon enough," said Korzeniowski. High-risk women include those who have breast cancer, a history of breast cancer, or a genetic predisposition.

The study, performed at McMaster University in Hamilton, Canada, included 59 lesions in 55 patients that were identified on breast MRI as indeterminate. "Of those indeterminate lesions, a significant number (22 percent) were proven positive for malignancy on follow-up and subsequent biopsy," he said.

"In our study, the cancer yield was substantial for indeterminate lesions identified on initial contrast-enhanced breast MRI which suggests that those lesions should be evaluated more aggressively to exclude malignancy and increase one's chances for survival," said Korzeniowski.


'/>"/>

Contact: Heather Curry
hcurry@acr-arrs.org
703-390-9822
American College of Radiology / American Roentgen Ray Society
Source:Eurekalert

Page: 1

Related medicine news :

1. Study evaluates importance of timeliness of care in breast cancer diagnosis and treatment
2. Smoking Ups Risk of Second Breast Cancer
3. Summer Brings Increased Demand For Breast and Body Enhancement
4. Largest Internet Supplier of Eternity Rings Pledges 10% of their Profits to the National Breast Cancer Foundation
5. Breakthrough in Predicting Invasive Breast Cancer
6. Comparison of available breast cancer risk assessment tools shows room for improvement
7. Breakthrough method predicts risk of invasive breast cancer
8. Cell study finds receptor can fight tamoxifen-resistant breast cancer cells
9. Breast Cancer Risks Not Same for Hispanic Women
10. Breast cancer risk factors differ among races
11. Global Summit on International Breast Health Targets Breast Health Improvements in Developing Countries, June 9-11, 2010, in Chicago
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
Breaking Medicine Technology: